{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:47:53Z","timestamp":1791478073846,"version":"4.3.4"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.msard.2017.06.002","type":"journal-article","created":{"date-parts":[[2017,6,10]],"date-time":"2017-06-10T17:25:12Z","timestamp":1497115512000},"page":"24-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["EBV and MS: Major cause, minor contribution or red-herring?"],"prefix":"10.1016","volume":"16","author":[{"given":"Sean","family":"Burnard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney J.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2017.06.002_bib1","doi-asserted-by":"crossref","first-page":"e1003220","DOI":"10.1371\/journal.ppat.1003220","article-title":"Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis","volume":"9","author":"Angelini","year":"2013","journal-title":"PLoS Pathog."},{"issue":"2","key":"10.1016\/j.msard.2017.06.002_bib2","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bbadis.2010.07.016","article-title":"Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants?","volume":"1812","author":"Antony","year":"2011","journal-title":"Biochim. Et. Biophys. Acta (BBA) - Mol. Basis Dis."},{"issue":"4","key":"10.1016\/j.msard.2017.06.002_bib3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.59566\/IJBS.2007.3292","article-title":"Multiple sclerosis and HERV-W\/MSRV: a multicentric study","volume":"3","author":"Arru","year":"2007","journal-title":"Int. J. Biomed. Sci.: Ijbs."},{"issue":"3","key":"10.1016\/j.msard.2017.06.002_bib4","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/blood-2007-07-101907","article-title":"Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines","volume":"111","author":"Bhaduri-McIntosh","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.msard.2017.06.002_bib5","doi-asserted-by":"crossref","unstructured":"Bjornevik K., Riise T., Bostrom I., Casetta L., Cortese M., Granieri E.. et al. 2016. Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study. Multiple sclerosis (Houndmills, Basingstoke, England).","DOI":"10.1177\/1352458516671028"},{"issue":"6","key":"10.1016\/j.msard.2017.06.002_bib6","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.4049\/jimmunol.1501097","article-title":"Th cell diversity in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"195","author":"Carbajal","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.msard.2017.06.002_bib7","doi-asserted-by":"crossref","first-page":"13995","DOI":"10.1038\/srep13995","article-title":"Latent virus infection upregulates CD40 expression facilitating enhanced autoimmunity in a model of multiple sclerosis","volume":"5","author":"Casiraghi","year":"2015","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.msard.2017.06.002_bib8","doi-asserted-by":"crossref","first-page":"e1002715","DOI":"10.1371\/journal.ppat.1002715","article-title":"Gammaherpesvirus latency accentuates EAE pathogenesis: relevance to Epstein-Barr virus and multiple sclerosis","volume":"8","author":"Casiraghi","year":"2012","journal-title":"PLoS Pathog."},{"issue":"5","key":"10.1016\/j.msard.2017.06.002_bib9","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1172\/JCI200523661","article-title":"Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis","volume":"115","author":"Cepok","year":"2005","journal-title":"J. Clin. Investig."},{"issue":"4","key":"10.1016\/j.msard.2017.06.002_bib10","doi-asserted-by":"crossref","first-page":"e94497","DOI":"10.1371\/journal.pone.0094497","article-title":"Quantitative detection of epstein-barr virus DNA in cerebrospinal fluid and blood samples of patients with relapsing-remitting multiple sclerosis","volume":"9","author":"Cocuzza","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.msard.2017.06.002_bib11","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1093\/cid\/ciu342","article-title":"Age-specific prevalence of Epstein-Barr virus infection among minnesota children: effects of race\/ethnicity and family environment","volume":"59","author":"Condon","year":"2014","journal-title":"Clin. Infect. Dis."},{"issue":"3","key":"10.1016\/j.msard.2017.06.002_bib12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0090-1229(88)90019-0","article-title":"T-cell-mediated suppression of Epstein-Barr virus-induced B lymphocyte activation in multiple sclerosis","volume":"48","author":"Craig","year":"1988","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.msard.2017.06.002_bib13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jneuroim.2015.05.019","article-title":"A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up","volume":"285","author":"Derfuss","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2017.06.002_bib14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jneuroim.2016.08.016","article-title":"The increased antibody response to Epstein-Barr virus in multiple sclerosis is restricted to selected virus proteins","volume":"299","author":"Dooley","year":"2016","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2017.06.002_bib15","first-page":"211","article-title":"Infectious mononucleosis","volume":"390","author":"Dunmire","year":"2015","journal-title":"Curr. Top. Microbiol. Immunol."},{"issue":"11","key":"10.1016\/j.msard.2017.06.002_bib16","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/intimm\/dxv025","article-title":"Inflammatory response of endothelial cells to a human endogenous retrovirus associated with multiple sclerosis is mediated by TLR4","volume":"27","author":"Duperray","year":"2015","journal-title":"Int. Immunol."},{"key":"10.1016\/j.msard.2017.06.002_bib17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jns.2016.01.013","article-title":"Epstein-Barr virus and multiple sclerosis. From evidence to therapeutic strategies","volume":"361","author":"Fernandez-Menendez","year":"2016","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.msard.2017.06.002_bib18","first-page":"175","volume":"2","author":"Fraser","year":"1979"},{"issue":"1\u20132","key":"10.1016\/j.msard.2017.06.002_bib19","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.jviromet.2006.05.013","article-title":"Epstein-Barr virus integrates frequently into chromosome 4q, 2q, 1q and 7q of Burkitt's lymphoma cell line (Raji)","volume":"136","author":"Gao","year":"2006","journal-title":"J. Virol. Methods"},{"issue":"12","key":"10.1016\/j.msard.2017.06.002_bib20","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1136\/jech.2003.018366","article-title":"Multiple sclerosis after infectious mononucleosis: record linkage study","volume":"58","author":"Goldacre","year":"2004","journal-title":"J. Epidemiol. Community Health"},{"key":"10.1016\/j.msard.2017.06.002_bib21","first-page":"173","article-title":"Chapter 11 - The epidemiology of multiple sclerosis: insights to a causal cascade\u2020","volume":"138","author":"Goodin","year":"2016"},{"issue":"1\u20132","key":"10.1016\/j.msard.2017.06.002_bib22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jneuroim.2006.08.008","article-title":"Frequency analysis of HLA-B7-restricted Epstein-Barr virus-specific cytotoxic T lymphocytes in patients with multiple sclerosis and healthy controls","volume":"180","author":"Gronen","year":"2006","journal-title":"J. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.msard.2017.06.002_bib23","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1128\/CMR.00006-09","article-title":"Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder","volume":"23","author":"Gulley","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"issue":"9","key":"10.1016\/j.msard.2017.06.002_bib24","doi-asserted-by":"crossref","first-page":"e12496","DOI":"10.1371\/journal.pone.0012496","article-title":"An updated meta-analysis of risk of multiple sclerosis following infectious Mononucleosis","volume":"5","author":"Handel","year":"2010","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.msard.2017.06.002_bib25","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1056\/NEJMoa0706383","article-title":"B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis","volume":"358","author":"Hauser","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.msard.2017.06.002_bib26","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1186\/gb-2013-14-1-r3","article-title":"The B cell transcription program mediates hypomethylation and overexpression of key genes in Epstein-Barr virus-associated proliferative conversion","volume":"14","author":"Hernando","year":"2013","journal-title":"Genome Biol."},{"issue":"2, Part B","key":"10.1016\/j.msard.2017.06.002_bib27","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.molimm.2015.07.041","article-title":"Peptide motif analysis predicts lymphocytic choriomeningitis virus as trigger for multiple sclerosis","volume":"67","author":"Hogeboom","year":"2015","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.msard.2017.06.002_bib28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaut.2015.06.010","article-title":"The immunogenetics of multiple sclerosis: a comprehensive review","volume":"64","author":"Hollenbach","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.msard.2017.06.002_bib29","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.msard.2016.04.006","article-title":"Human endogenous retrovirus W in brain lesions: rationale for targeted therapy in multiple sclerosis","volume":"8","author":"van Horssen","year":"2016","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"13 Pt 2","key":"10.1016\/j.msard.2017.06.002_bib30","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1212\/01.wnl.0000294325.63006.f8","article-title":"Integrating risk factors: hla-drb1*1501 and Epstein-Barr virus in multiple sclerosis","volume":"70","author":"De Jager","year":"2008","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.msard.2017.06.002_bib31","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1002\/eji.200939761","article-title":"Intrathecal immune responses to EBV in early MS","volume":"40","author":"Jaquiery","year":"2010","journal-title":"Eur. J. Immunol."},{"issue":"9","key":"10.1016\/j.msard.2017.06.002_bib32","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.4049\/jimmunol.1103100","article-title":"HLA-B7-restricted EBV-specific CD8+ T cells are dysregulated in multiple sclerosis","volume":"188","author":"Jilek","year":"2012","journal-title":"J. Immunol."},{"issue":"Pt 7","key":"10.1016\/j.msard.2017.06.002_bib33","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/brain\/awn108","article-title":"Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis","volume":"131","author":"Jilek","year":"2008","journal-title":"Brain: J. Neurol."},{"key":"10.1016\/j.msard.2017.06.002_bib34","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/v8020051","article-title":"Infectious mononucleosis triggers generation of IgG auto-antibodies against native myelin oligodendrocyte glycoprotein","volume":"8","author":"Kakalacheva","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.msard.2017.06.002_bib35","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1038\/emm.2014.84","article-title":"Epstein-Barr virus latent genes","volume":"47","author":"Kang","year":"2015","journal-title":"Exp. Mol. Med."},{"issue":"1","key":"10.1016\/j.msard.2017.06.002_bib36","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/ane.12417","article-title":"Antivirus immune activity in multiple sclerosis correlates with MRI activity","volume":"133","author":"Latham","year":"2016","journal-title":"Acta Neurol. Scand."},{"issue":"6","key":"10.1016\/j.msard.2017.06.002_bib37","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ana.21978","article-title":"Primary infection with the epstein-barr virus and risk of multiple sclerosis","volume":"67","author":"Levin","year":"2010","journal-title":"Ann. Neurol."},{"issue":"1\u20132","key":"10.1016\/j.msard.2017.06.002_bib38","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jneuroim.2010.08.009","article-title":"Epstein-Barr virus and multiple sclerosis: cellular immune response and cross-reactivity","volume":"229","author":"Lindsey","year":"2010","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2017.06.002_bib39","unstructured":"Lovett-Racke AE. Contribution of EAE to understanding and treating multiple sclerosis. Journal of Neuroimmunology."},{"issue":"10","key":"10.1016\/j.msard.2017.06.002_bib40","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1136\/jnnp-2011-300174","article-title":"Epstein-Barr virus and multiple sclerosis","volume":"82","author":"Lucas","year":"2011","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"21","key":"10.1016\/j.msard.2017.06.002_bib41","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1056\/NEJMcp1001116","article-title":"Infectious mononucleosis","volume":"362","author":"Luzuriaga","year":"2010","journal-title":"New Engl. J. Med."},{"issue":"8","key":"10.1016\/j.msard.2017.06.002_bib42","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1084\/jem.20072397","article-title":"EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-\u03b3 and IL-2","volume":"205","author":"L\u00fcnemann","year":"2008","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.msard.2017.06.002_bib43","doi-asserted-by":"crossref","first-page":"e78474","DOI":"10.1371\/journal.pone.0078474","article-title":"Activation of MSRV-type endogenous retroviruses during infectious mononucleosis and Epstein-Barr virus latency: the missing link with multiple sclerosis?","volume":"8","author":"Mameli","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.msard.2017.06.002_bib44","doi-asserted-by":"crossref","first-page":"e44991","DOI":"10.1371\/journal.pone.0044991","article-title":"Expression and activation by Epstein Barr virus of human endogenous retroviruses-W in blood cells and astrocytes: inference for multiple sclerosis","volume":"7","author":"Mameli","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.msard.2017.06.002_bib45","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1002\/jmv.21764","article-title":"Detection of viral DNA sequences in the cerebrospinal fluid of patients with multiple sclerosis","volume":"82","author":"Mancuso","year":"2010","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.msard.2017.06.002_bib46","doi-asserted-by":"crossref","first-page":"544","DOI":"10.3389\/fimmu.2015.00544","article-title":"The role of latently infected B cells in CNS autoimmunity","volume":"6","author":"M\u00e1rquez","year":"2015","journal-title":"Front. Immunol."},{"issue":"10","key":"10.1016\/j.msard.2017.06.002_bib47","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1080\/14737175.2016.1227242","article-title":"Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis","volume":"16","author":"Menge","year":"2016","journal-title":"Expert Rev. Neurother."},{"issue":"7","key":"10.1016\/j.msard.2017.06.002_bib48","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.autrev.2016.03.006","article-title":"Therapeutic strategies targeting B-cells in multiple sclerosis","volume":"15","author":"Milo","year":"2016","journal-title":"Autoimmun. Rev."},{"issue":"2","key":"10.1016\/j.msard.2017.06.002_bib49","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1001\/archneur.62.2.258","article-title":"EFfect of rituximab on the peripheral blood and cerebrospinal fluid b cells in patients with primary progressive multiple sclerosis","volume":"62","author":"Monson","year":"2005","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.msard.2017.06.002_bib50","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3389\/fimmu.2015.00647","article-title":"Multiple sclerosis between genetics and infections: human endogenous retroviruses in monocytes and macrophages","volume":"6","author":"Morandi","year":"2015","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.msard.2017.06.002_bib51","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1001\/archneur.64.1.72","article-title":"Multiple sclerosis after infectious mononucleosis","volume":"64","author":"Nielsen","year":"2007","journal-title":"Arch. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2017.06.002_bib52","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1177\/1352458515588581","article-title":"Intrathecal CD8 T-cells of multiple sclerosis patients recognize lytic Epstein-Barr virus proteins","volume":"22","author":"van Nierop","year":"2016","journal-title":"Mult. Scler. (Houndmills Basingstoke Engl.)."},{"issue":"1","key":"10.1016\/j.msard.2017.06.002_bib53","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1038\/emm.2014.82","article-title":"EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management","volume":"47","author":"Ok","year":"2015","journal-title":"Exp. Mol. Med."},{"issue":"2","key":"10.1016\/j.msard.2017.06.002_bib54","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1177\/1352458512449682","article-title":"The risk of developing multiple sclerosis in individuals seronegative for Epstein-Barr virus: a meta-analysis","volume":"19","author":"Pakpoor","year":"2013","journal-title":"Mult. Scler. J."},{"issue":"7","key":"10.1016\/j.msard.2017.06.002_bib55","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1002\/eji.200323148","article-title":"Exacerbation of experimental autoimmune encephalomyelitis in rodents infected with murine gammaherpesvirus-68","volume":"33","author":"Peacock","year":"2003","journal-title":"Eur. J. Immunol."},{"issue":"Pt 5","key":"10.1016\/j.msard.2017.06.002_bib56","doi-asserted-by":"crossref","first-page":"e137","DOI":"10.1093\/brain\/awp296","article-title":"Epstein Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis","volume":"133","author":"Peferoen","year":"2010","journal-title":"Brain: J. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2017.06.002_bib57","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1038\/cti.2014.25","article-title":"Epstein\u2013Barr virus and multiple sclerosis: potential opportunities for immunotherapy","volume":"3","author":"Pender","year":"2014","journal-title":"Clin. Transl. Immunol."},{"issue":"5","key":"10.1016\/j.msard.2017.06.002_bib58","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/jnnp.2008.161018","article-title":"Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis","volume":"80","author":"Pender","year":"2009","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"5","key":"10.1016\/j.msard.2017.06.002_bib59","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1136\/jnnp.2008.161018","article-title":"Decreased T cell reactivity to Epstein\u2013Barr virus infected lymphoblastoid cell lines in multiple sclerosis","volume":"80","author":"Pender","year":"2009","journal-title":"J. Neurol., Neurosurg., Psychiatry"},{"key":"10.1016\/j.msard.2017.06.002_bib60","series-title":"Epstein-Barr Virus-specific Adoptive Immunotherapy for Progressive Multiple Sclerosis","first-page":"1541","volume":"20","author":"Pender","year":"2014"},{"issue":"11","key":"10.1016\/j.msard.2017.06.002_bib61","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.it.2003.09.005","article-title":"Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases","volume":"24","author":"Pender","year":"2003","journal-title":"Trends Immunol."},{"issue":"1","key":"10.1016\/j.msard.2017.06.002_bib62","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/13550280590901741","article-title":"Human endogenous retrovirus (HERV)-W ENV and gag proteins: physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions","volume":"11","author":"Perron","year":"2005","journal-title":"J. Neurovirol."},{"issue":"3","key":"10.1016\/j.msard.2017.06.002_bib63","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1084\/jem.20041542","article-title":"CD8(+) immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells","volume":"201","author":"Pudney","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.msard.2017.06.002_bib64","article-title":"Ongoing increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 50-year study","author":"Ribbons","year":"2016","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2017.06.002_bib65","doi-asserted-by":"crossref","DOI":"10.1038\/icb.2016.55","article-title":"Interferon-[beta] therapy specifically reduces pathogenic memory B cells in multiple sclerosis patients by inducing a FAS-mediated apoptosis","author":"Rizzo","year":"2016","journal-title":"Immunol. Cell Biol."},{"issue":"4","key":"10.1016\/j.msard.2017.06.002_bib66","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/gbe\/evu054","article-title":"Genome-wide analysis of wild-type Epstein-Barr virus genomes derived from healthy individuals of the 1000 genomes project","volume":"6","author":"Santpere","year":"2014","journal-title":"Genome Biol. Evol."},{"issue":"14","key":"10.1016\/j.msard.2017.06.002_bib67","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0b013e3181d865a1","article-title":"Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis","volume":"74","author":"Sargsyan","year":"2010","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.msard.2017.06.002_bib68","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1084\/jem.20071030","article-title":"Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain","volume":"204","author":"Serafini","year":"2007","journal-title":"J. Exp. Med."},{"issue":"7","key":"10.1016\/j.msard.2017.06.002_bib69","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1097\/NEN.0b013e3181e332ec","article-title":"Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation","volume":"69","author":"Serafini","year":"2010","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"17","key":"10.1016\/j.msard.2017.06.002_bib70","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1212\/WNL.0b013e3181dad57e","article-title":"Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk","volume":"74","author":"Simon","year":"2010","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2017.06.002_bib71","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/1756285615601933","article-title":"The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects","volume":"9","author":"Sorensen","year":"2016","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"1","key":"10.1016\/j.msard.2017.06.002_bib72","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/gene.2011.42","article-title":"Epstein-Barr virus and multiple sclerosis: interaction with HLA","volume":"13","author":"Sundqvist","year":"2012","journal-title":"Genes Immun."},{"issue":"1\u20132","key":"10.1016\/j.msard.2017.06.002_bib73","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jneuroim.2009.08.004","article-title":"Antibodies to specific EBNA-1 domains and HLA DRB1*1501 interact as risk factors for multiple sclerosis","volume":"215","author":"Sundstrom","year":"2009","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"10.1016\/j.msard.2017.06.002_bib74","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0002-9440(10)63184-7","article-title":"Integration of Epstein-Barr virus into chromosome 6q15 of Burkitt lymphoma cell line (Raji) induces loss of BACH2 expression","volume":"164","author":"Takakuwa","year":"2004","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.msard.2017.06.002_bib75","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1212\/WNL.0b013e31823ed057","article-title":"Association of innate immune activation with latent Epstein-Barr virus in active MS lesions","volume":"78","author":"Tzartos","year":"2012","journal-title":"Neurology"},{"issue":"Pt 12","key":"10.1016\/j.msard.2017.06.002_bib76","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1093\/brain\/awp200","article-title":"Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain","volume":"132","author":"Willis","year":"2009","journal-title":"Brain: J. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2017.06.002_bib77","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.smim.2011.01.007","article-title":"T cell receptor recognition of self and foreign antigens in the induction of autoimmunity","volume":"23","author":"Wucherpfennig","year":"2011","journal-title":"Semin. Immunol."},{"issue":"5","key":"10.1016\/j.msard.2017.06.002_bib78","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0092-8674(95)90348-8","article-title":"Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein","volume":"80","author":"Wucherpfennig","year":"1995","journal-title":"Cell"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034817301335?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034817301335?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:40:23Z","timestamp":1761900023000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034817301335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":78,"alternative-id":["S2211034817301335"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2017.06.002","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727882220.793568398","asserted-by":"object"}]},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"EBV and MS: Major cause, minor contribution or red-herring?","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2017.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}